Table 1.
The clinical trials on immune checkpoints and other therapeutic targets for HCC in recent years
| ClinicalTrials.govIdentifier | Trial name | Agent | Target | Endpoints | Phase | Actual Enrollment | Recruitment Status |
|---|---|---|---|---|---|---|---|
| NCT03695250 | BMS-986205 vs Nivolumab | IDO1, PD-1 | Safety/Tolerability/ORR | 1/2 | 8 | Active, not recruiting | |
| NCT01658878 | CheckMate040 | Nivolumab plus Cabozantinib +/- Ipilimumab | PD-1, CTLA-4, TKI | Safety/Tolerability/ORR | 1/2 | 659 | Active, not recruiting |
| NCT03006926 | Pembrolizumab plus Lenvatinib | PD-1, TKI | Safety | 1 | 104 | Active, not recruiting | |
| NCT03222076 | Nivolumab +/- Ipilimumab |
PD-1, CTLA-4 | Safety/Tolerability | 2 | 30 | Active, not recruiting | |
| NCT03434379 | IMbrave150 | Atezolizumab plus Bevacizumab vs Sorafenib | PD-L1, VEGFR, TKI | PFS/OS | 3 | 558 | Active, not recruiting |
| NCT03383458 | CheckMate 9DX | Nivolumab | PD-1 | RFS | 3 | 545 | Active, not recruiting |
| NCT03867084 | KEYNOTE-937 | Pembrolizumab | PD-1 | RFS/OS | 3 | 950 | Recruiting |
| NCT03847428 | EMERALD-2 | Durvalumab +/- Bevacizumab | PD-L1, VEGFR | RFS | 3 | 888 | Recruiting |
| NCT03859128 | JUPITER 04 | Toripalimab | PD-1 | RFS | 2/3 | 402 | Active, not recruiting |
| NCT04102098 | IMbrave050 | Atezolizumab plus Bevacizumab | PD-L1, VEGFR | RFS | 3 | 668 | Active, not recruiting |